# Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

> **NCT06592924** · PHASE3 · RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 830 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)

## Interventions

- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide
- **DRUG:** Apalutamide
- **DRUG:** Darolutamide (BAY 1841788)
- **DRUG:** Docetaxel
- **DRUG:** ADT

## Key facts

- **NCT ID:** NCT06592924
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-28
- **Primary completion:** 2031-03-14
- **Final completion:** 2031-04-15
- **Target enrollment:** 830 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06592924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06592924, "Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06592924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*